FAIM
NKTR icon

Financial Advocates Investment Management’s Nektar Therapeutics NKTR Stock Holding History

Financial Advocates Investment Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-786
Closed -$242K – 806
2021
Q1 		$242K Buy
+786
New +$245K 0.02% 670
2020
Q3 		– Sell
-221
Closed -$405K – 672
2020
Q2 		$405K Buy
+221
New +$69K 0.04% 398

Other funds holding NKTR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Financial Advocates Investment Management's NKTR Position: Q3 2023 in Review

Financial Advocates Investment Management sold out of Nektar Therapeutics (NKTR) in Q3 2023, closing a stake of 703 shares — an estimated $6.07K sold.

Financial Advocates Investment Management first reported a position in NKTR in Q3 2019 and held it in 10 quarters. The position peaked at $1.76M in Q4 2021. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2023.

  • Financial Advocates Investment Management reported no remaining Nektar Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Financial Advocates Investment Management sold 703 Nektar Therapeutics shares in Q3 2023, an estimated $6.07K.
  • Financial Advocates Investment Management first reported a position in Nektar Therapeutics in Q3 2019 and held it in 10 quarters.
  • Financial Advocates Investment Management's Nektar Therapeutics position peaked at $1.76M in Q4 2021.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2023.

Based on Financial Advocates Investment Management's 13F filing for Q3 2023, filed 27 Oct 2023.